US2022362378A1PendingUtilityA1

Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists

71
Assignee: GENENTECH INCPriority: May 31, 2012Filed: Feb 14, 2022Published: Nov 17, 2022
Est. expiryMay 31, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Heather MaeckerBryan Irving
A61K 39/39558A61P 1/04A61K 2039/507A61K 39/395C07K 16/2827A61P 35/00A61K 2039/505A61P 43/00C07K 16/22A61K 31/282A61K 31/513A61K 31/519A61K 39/3955C07K 16/28
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of a PD-1 axis binding antagonist, oxaliplatin, leucovorin and 5-FU. 
     
     
         2 . The method of  claim 1 , wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist and a PD-L2 binding antagonist. 
     
     
         3 . The method of  claim 2 , wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist. 
     
     
         4 . The method of  claim 3 , wherein the PD-1 binding antagonist inhibits the binding of PD-1 to its ligand binding partners. 
     
     
         5 . The method of  claim 4 , wherein the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1. 
     
     
         6 . The method of  claim 4 , wherein the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L2. 
     
     
         7 . The method of  claim 4 , wherein the PD-1 binding antagonist inhibits the binding of PD-1 to both PD-L1 and PD-L2. 
     
     
         8 . The method of  claim 4 , wherein the PD-1 binding antagonist is an antibody. 
     
     
         9 . The method of  claim 8 , wherein the PD-1 binding antagonist is MDX-1106. 
     
     
         10 . The method of  claim 8 , wherein the PD-1 binding antagonist is Merck 3745. 
     
     
         11 . The method of  claim 8 , wherein the PD-1 binding antagonist is CT-011. 
     
     
         12 . The method of  claim 2 , wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist. 
     
     
         13 . The method of  claim 12 , wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1. 
     
     
         14 . The method of  claim 12 , wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to B7-1. 
     
     
         15 . The method of  claim 12 , wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to both PD-1 and B7-1. 
     
     
         16 . The method of  claim 12 , wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody. 
     
     
         17 . The method of  claim 16 , wherein the anti-PD-L1 antibody is a monoclonal antibody.

Join the waitlist — get patent alerts

Track US2022362378A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.